533 related articles for article (PubMed ID: 19112682)
1. Toll-free number for reporting adverse events on labeling for human drug products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Oct; 73(209):63886-97. PubMed ID: 19112682
[TBL] [Abstract][Full Text] [Related]
2. Toll-free number for reporting adverse events on labeling for human drug products. Interim final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Jan; 73(2):402-4. PubMed ID: 18389912
[TBL] [Abstract][Full Text] [Related]
3. Registration of food facilities under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Oct; 70(190):57505-9. PubMed ID: 16200686
[TBL] [Abstract][Full Text] [Related]
4. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls--FDA. Final rule.
Fed Regist; 1993 Aug; 58(147):41348-54. PubMed ID: 10127711
[TBL] [Abstract][Full Text] [Related]
5. Applications for Food and Drug Administration approval to market a new drug; postmarketing reports; reporting information about authorized generic drugs. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2008 Sep; 73(189):56487-91. PubMed ID: 18985960
[TBL] [Abstract][Full Text] [Related]
6. Human drugs and biologics; determination that informed consent is NOT feasible or is contrary to the best interests of recipients; revocation of 1990 interim final rule; establishment of new interim final rule. Food and Drug Administration, HHS. Interim final rule; opportunity for public comment.
Fed Regist; 1999 Oct; 64(192):54180-9. PubMed ID: 11010702
[TBL] [Abstract][Full Text] [Related]
7. Requirements on content and format of labeling for human prescription drug and biological products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2006 Jan; 71(15):3921-97. PubMed ID: 16479698
[TBL] [Abstract][Full Text] [Related]
8. Distribution of blood derivatives by registered blood establishments that qualify as health care entities; Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; delay of applicability date. Final rule; delay of applicability date.
Food and Drug Administration, HHS
Fed Regist; 2006 Nov; 71(218):66108-9. PubMed ID: 17099971
[TBL] [Abstract][Full Text] [Related]
9. Dissemination of information on unapproved/new uses for marketed drugs, biologics, and devices--FDA. Final rule.
Fed Regist; 1998 Nov; 63(224):64556-88. PubMed ID: 10339052
[TBL] [Abstract][Full Text] [Related]
10. Prescription Drug Marketing Act of 1987; Prescription Drug Amendments of 1992; policies, requirements, and administrative procedures; delay of effective date. Final rule; delay of effective date.
Food and Drug Administration, HHS
Fed Regist; 2004 Feb; 69(35):8105-7. PubMed ID: 14997866
[TBL] [Abstract][Full Text] [Related]
11. Labeling and effectiveness testing; sunscreen drug products for over-the-counter human use; delay of compliance dates. Final rule; delay of compliance dates; request for comments.
Food and Drug Administration, HHS
Fed Regist; 2012 May; 77(92):27591-3. PubMed ID: 22606729
[TBL] [Abstract][Full Text] [Related]
12. Expedited safety reporting requirements for human drug and biological products; correction--FDA. Final rule; correction.
Fed Regist; 1998 Mar; 63(58):14611-2. PubMed ID: 10177754
[TBL] [Abstract][Full Text] [Related]
13. Sunscreen drug products for over-the-counter human use; final monograph. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 May; 64(98):27666-93. PubMed ID: 10558542
[TBL] [Abstract][Full Text] [Related]
14. Food labeling: health claims; garlic, reduction of serum cholesterol, and the risk of cardiovascular disease in adults--FDA. Interim final rule.
Fed Regist; 1998 Jun; 63(119):34110-2. PubMed ID: 10180290
[TBL] [Abstract][Full Text] [Related]
15. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; revision of certain labeling controls. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2012 Mar; 77(54):16158-63. PubMed ID: 22479732
[TBL] [Abstract][Full Text] [Related]
16. Applications for Food and Drug Administration application approval to market a new drug; revision of postmarketing reporting requirements. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2007 Oct; 72(201):58993-9000. PubMed ID: 17966558
[TBL] [Abstract][Full Text] [Related]
17. Skin protectant drug products for over-the-counter human use; astringent drug products; final monograph; direct final rule. Direct final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(114):35290-3. PubMed ID: 12807133
[TBL] [Abstract][Full Text] [Related]
18. Drug labeling; sodium labeling for over-the-counter drugs. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2004 Nov; 69(228):69278-80. PubMed ID: 15570675
[TBL] [Abstract][Full Text] [Related]
19. Food labeling: health claims; omega-3 fatty acids and the risk in adults of cardiovascular disease--FDA. Interim final rule.
Fed Regist; 1998 Jun; 63(119):34107-10. PubMed ID: 10180289
[TBL] [Abstract][Full Text] [Related]
20. Food labeling: health claims; chromium and the risk in adults of hyperglycemia and the effects of glucose intolerance--FDA. Interim final rule.
Fed Regist; 1998 Jun; 63(119):34104-7. PubMed ID: 10180288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
